Second attempt of Cabergoline withdrawal in patients with prolactinomas after a failed first attempt : is it worthwhile?
Successful discontinuation of cabergoline (CAB) treatment has been reported in 31 to 74% of prolactinomas patients treated for at least two years. In contrast, it is not well established whether CAB therapy can be successfully withdrawn after a failed first attempt. This prospective open trial was...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2015-02-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fendo.2015.00011/full |